Galectin 3 and incident atrial fibrillation in the community
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background Galectin 3 (Gal-3) is a potential mediator of cardiac fibrosis, and Gal-3 concentrations predict incident heart failure. The same mechanisms that lead to cardiac fibrosis in heart failure may influence development of atrial fibrosis and atrial fibrillation (AF). We examined the association of Gal-3 and incident AF in the community. Methods Plasma Gal-3 concentrations were measured in 3,306 participants of the Framingham Offspring cohort who attended the sixth examination cycle (1995–1998, mean age 58 years, 54% women). Cox proportional hazards regression models were used to assess the association of baseline Gal-3 concentrations and incident AF. Results Over a median follow-up period of 10 years, 250 participants developed incident AF. Crude incidence rates of AF by increasing sex-specific Gal-3 quartiles were 3.7%, 5.9%, 9.1%, and 11.5% (log-rank test P < .0001). In age- and sex-adjusted analyses, each 1-SD increase in loge-Gal-3 was associated with a 19% increased hazard of incident AF (hazard ratio 1.19, 95% CI 1.05–1.36, P = .009). This association was not significant after adjustment for traditional clinical AF risk factors (hazard ratio 1.12, 95% CI 0.98–1.28, P = .10). Conclusion Higher circulating Gal-3 concentrations were associated with increased risk of developing AF over the subsequent 10 years in age- and sex-adjusted analyses but not after accounting for other traditional clinical AF risk factors. Our results do not support a role for Gal-3 in AF risk prediction. Further studies are needed to evaluate whether Gal-3 plays a role in the development of AF substrate similar to HF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493 · cited 1×
“ry-free Net Reclassification Improvement (NRI) metric for the addition of Gal-3 in models containing traditional clinical risk factors of AF development.(31,32) Statistical analyses were conducted using SAS version 9.”
MethodSelf-citationThe natural history of congestive heart failure: the Framingham study
McKee, P. A., Castelli, W. P., McNamara, P. M., & Kannel, W. B. (1971) · New England Journal of Medicine · doi:10.1056/nejm197112232852601 · Cited by 3,448
Wang, T. J., Larson, M. G., Levy, D., Vasan, R. S., Leip, E. P., Wolf, P. A., D’Agostino, R. B., Murabito, J. M., Kannel, W. B., & Benjamin, E. J. (2003) · Circulation · doi:10.1161/01.cir.0000072767.89944.6e · Cited by 1,970 · cited 1×
“Specifically, AF often precedes or follows the development of HF, and the effects of AF and HF in combination yield a particularly adverse prognosis.(3) Pathophysiological”
BackgroundSelf-citationAtrial Remodeling and Atrial Fibrillation: Mechanisms and Implications
Nattel, S., Burstein, B., & Dobrev, D. (2008) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.107.754564 · Cited by 1,124
Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study.
Vaziri, S. M., Larson, M. G., Benjamin, E. J., & Levy, D. (1994) · Circulation · doi:10.1161/01.cir.89.2.724 · Cited by 1,073
Self-citationGoette, A., Staack, T., Röcken, C., Arndt, M., Geller, J. C., Huth, C., Ansorge, S., Klein, H. U., & Lendeckel, U. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00611-2 · Cited by 583
Galectin-3 Expression and Secretion Links Macrophages to the Promotion of Renal Fibrosis
Henderson, N. C., Mackinnon, A. C., Farnworth, S. L., Kipari, T., Haslett, C., Iredale, J. P., Liu, F.-T., Hughes, J., & Sethi, T. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070726 · Cited by 562 · cited 1×
“In experimental studies, Gal-3 was a central component in the development of myocardial and vascular fibrosis,(12,13) likely by activating TGF-β–mediated myofibroblast activation and stimulating matrix production.(14,15) In human studies, circulating Gal-3 concentrations predicted incident HF in the community(16) and…”
BackgroundVasan, R. S., Benjamin, E. J., Larson, M. G., Leip, E. P., Wang, T. J., Wilson, P. W. F., & Levy, D. (2002) · JAMA · doi:10.1001/jama.288.10.1252 · Cited by 493 · cited 1×
“A total of 2,321 participants included in this analysis also had routine M-mode and 2-dimensional echocardiography.(25) Left ventricular (LV) end-diastolic dimension (LVDD), LV endsystolic dimension, left atrial end-systolic diameter, and enddiastolic LV septal and posterior wall thicknesses were measured according to…”
MethodSelf-citation
Cited by
Cardiac Fibrosis in Patients With Atrial Fibrillation
Dzeshka, M. S., Lip, G. Y. H., Snezhitskiy, V., & Shantsila, E. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1313 · Cited by 552
Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z
Sciacchitano, S., Lavra, L., Morgante, A., Ulivieri, A., Magi, F., De Francesco, G., Bellotti, C., Salehi, L., & Ricci, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020379 · Cited by 377
Diagnosis, pathophysiology, and management of exercise-induced arrhythmias
Guasch, E., & Mont, L. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.173 · Cited by 134
Association of sST2 and hs-CRP levels with new-onset atrial fibrillation in coronary artery disease
Nortamo, S., Ukkola, O., Lepojärvi, S., Kenttä, T., Kiviniemi, A., Junttila, J., Huikuri, H., & Perkiömäki, J. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.07.022 · Cited by 65
Fashanu, O. E., Norby, F. L., Aguilar, D., Ballantyne, C. M., Hoogeveen, R. C., Chen, L. Y., Soliman, E. Z., Alonso, A., & Folsom, A. R. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.07.001 · Cited by 50
Metadata
- Authors
- Ho, J. E., Yin, X., Levy, D., Vasan, R. S., Magnani, J. W., Ellinor, P. T., McManus, D. D., Lubitz, S. A., Larson, M. G., & Benjamin, E. J.
- Venue
- American Heart Journal
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 167
- Issue
- 5
- Pages
- 729-734.e1
- ISSN
- 0002-8703 (ISSN-L)
- OpenAlex
- W1973273161
- Cited by
- 118
- References
- 9
- FWCI
- 10.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Galectin 3 and incident atrial fibrillation in the community. https://app.cochat.ai/papers/10.1016/j.ahj.2014.02.009
- The paper
- Ho, J. E., Yin, X., Levy, D., Vasan, R. S., Magnani, J. W., Ellinor, P. T., McManus, D. D., Lubitz, S. A., Larson, M. G., & Benjamin, E. J. (2014). Galectin 3 and incident atrial fibrillation in the community. American Heart Journal. https://doi.org/10.1016/j.ahj.2014.02.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.